Adaptimmune Historical Income Statement
| ADAP Stock | USD 0.84 0.03 3.45% |
Historical analysis of Adaptimmune Therapeutics income statement accounts such as Interest Expense of 1.6 M, Selling General Administrative of 37.2 M or Other Operating Expenses of 116.9 M can show how well Adaptimmune Therapeutics Plc performed in making a profits. Evaluating Adaptimmune Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Adaptimmune Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Adaptimmune Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Adaptimmune Therapeutics is a good buy for the upcoming year.
Adaptimmune |
About Adaptimmune Income Statement Analysis
Adaptimmune Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Adaptimmune Therapeutics shareholders. The income statement also shows Adaptimmune investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Adaptimmune Therapeutics Income Statement Chart
Add Fundamental
Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Adaptimmune Therapeutics. It is also known as Adaptimmune Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Net Income Applicable To Common Shares
The net income that remains after preferred dividends have been deducted, available to common shareholders.Most accounts from Adaptimmune Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Adaptimmune Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptimmune Therapeutics Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At this time, Adaptimmune Therapeutics' Interest Expense is relatively stable compared to the past year. As of 10/19/2024, Total Other Income Expense Net is likely to grow to about 9.7 M, while Other Operating Expenses is likely to drop slightly above 116.9 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Net Interest Income | 1.1M | 1.5M | 6.0M | 6.3M | Interest Income | 1.1M | 1.5M | 6.0M | 6.3M |
Adaptimmune Therapeutics income statement Correlations
Click cells to compare fundamentals
Adaptimmune Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Adaptimmune Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 8.0M | 7.7M | 6.6M | 6.1M | 9.9M | 5.2M | |
| Interest Expense | 2.8M | 3.5M | 4.9M | 1.0M | 1.2M | 1.6M | |
| Selling General Administrative | 43.4M | 45.8M | 57.3M | 63.4M | 71.8M | 37.2M | |
| Other Operating Expenses | 140.9M | 137.4M | 168.4M | 191.1M | 198.3M | 116.9M | |
| Operating Income | (139.8M) | (133.4M) | (162.2M) | (164.0M) | (137.8M) | (144.7M) | |
| Ebit | (139.8M) | (133.5M) | (162.2M) | (164.0M) | (137.8M) | (144.7M) | |
| Research Development | 97.5M | 91.6M | 111.1M | 127.7M | 142.6M | 81.3M | |
| Ebitda | (131.8M) | (125.8M) | (155.7M) | (157.9M) | (127.9M) | (134.3M) | |
| Cost Of Revenue | 97.5M | 91.6M | 111.1M | 127.7M | 9.9M | 9.4M | |
| Total Operating Expenses | 140.9M | 137.4M | 168.4M | 191.1M | 188.4M | 116.0M | |
| Income Before Tax | (136.9M) | (129.9M) | (157.3M) | (163.0M) | (128.6M) | (135.0M) | |
| Total Other Income Expense Net | 2.8M | 3.5M | 4.9M | 1.0M | 9.2M | 9.7M | |
| Net Income | (137.2M) | (130.1M) | (158.1M) | (165.5M) | (114.3M) | (120.0M) | |
| Income Tax Expense | 242K | 162K | 791K | 2.5M | (14.3M) | (13.5M) | |
| Total Revenue | 1.1M | 4.0M | 6.1M | 27.1M | 60.5M | 63.5M | |
| Gross Profit | (96.4M) | (87.6M) | (104.9M) | (100.6M) | 50.7M | 53.2M | |
| Net Income From Continuing Ops | (137.2M) | (130.1M) | (158.1M) | (165.5M) | (113.9M) | (119.6M) | |
| Net Income Applicable To Common Shares | (137.2M) | (130.1M) | (158.1M) | (165.5M) | (148.9M) | (141.5M) | |
| Tax Provision | 242K | 162K | 791K | 2.5M | 1.3M | 832.7K | |
| Interest Income | 2.8M | 2.3M | 1.1M | 1.5M | 6.0M | 6.3M | |
| Net Interest Income | 2.8M | 2.3M | 1.1M | 1.5M | 6.0M | 6.3M | |
| Non Operating Income Net Other | (12.7M) | 2.8M | 1.2M | 3.9M | 4.4M | 4.7M | |
| Reconciled Depreciation | 8.0M | 7.6M | 6.6M | 6.1M | 9.8M | 8.1M |
Pair Trading with Adaptimmune Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptimmune Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Adaptimmune Stock
| 0.77 | VALN | Valneva SE ADR | PairCorr |
| 0.83 | DYAI | Dyadic International | PairCorr |
| 0.83 | ERNA | Eterna Therapeutics | PairCorr |
Moving against Adaptimmune Stock
| 0.71 | GNFT | Genfit | PairCorr |
| 0.66 | GILD | Gilead Sciences | PairCorr |
| 0.63 | BMY | Bristol Myers Squibb | PairCorr |
| 0.58 | WVE | Wave Life Sciences | PairCorr |
| 0.41 | A | Agilent Technologies Fiscal Year End 18th of November 2024 | PairCorr |
The ability to find closely correlated positions to Adaptimmune Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptimmune Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptimmune Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptimmune Therapeutics Plc to buy it.
The correlation of Adaptimmune Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptimmune Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptimmune Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptimmune Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.